CWM
AQST icon

Cahill Wealth Management’s Aquestive Therapeutics AQST Stock Holding History

Cahill Wealth Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$633K Buy
218,381
+75,330
+53% +$228K 0.32% 33
2024
Q4 		$509K Buy
143,051
+110
+0.1% +$507 0.26% 36
2024
Q3 		$712K Buy
142,941
+24,380
+21% +$94.9K 0.37% 30
2024
Q2 		$308K Buy
118,561
+32,348
+38% +$108K 0.18% 41
2024
Q1 		$367K Buy
+86,213
New +$287K 0.21% 40

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Cahill Wealth Management's AQST Position: Q1 2025 in Review

Cahill Wealth Management increased its Aquestive Therapeutics (AQST) stake by 53% in Q1 2025, buying an estimated $228K and bringing the position to 218,381 shares worth $633K. The position accounts for 0.32% of the portfolio, ranked #33.

Cahill Wealth Management first reported a position in AQST in Q1 2024 and has held it in 5 quarters since. The position peaked at $712K in Q3 2024. 121 funds tracked by Wall St. Rank hold AQST as of Q1 2025.

  • Cahill Wealth Management held 218,381 shares of Aquestive Therapeutics worth $633K as of Q1 2025.
  • Cahill Wealth Management bought 75,330 Aquestive Therapeutics shares in Q1 2025, an estimated $228K.
  • Aquestive Therapeutics made up 0.32% of Cahill Wealth Management's portfolio in Q1 2025, its #33 holding.
  • Cahill Wealth Management first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Cahill Wealth Management's Aquestive Therapeutics position peaked at $712K in Q3 2024.
  • 121 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2025.

Based on Cahill Wealth Management's 13F filing for Q1 2025, filed 12 May 2025.